Expression of endothelin-1 in the lungs of patients with pulmonary hypertension

Adel Giaid, Masashi Yanagisawa, David Langleben, René P. Michel, Robert Levy, Hani Shennib, Sadao Kimura, Tomoh Masaki, William P. Duguid, Duncan J. Stewart

Research output: Contribution to journalArticle

1515 Citations (Scopus)

Abstract

Background. Pulmonary hypertension is characterized by an increase in vascular tone or an abnormal proliferation of muscle cells in the walls of small pulmonary arteries. Endothelin-1 is a potent endothelium-derived vasoconstrictor peptide with important mitogenic properties. It has therefore been suggested that endothelin-1 may contribute to increases in pulmonary arterial tone or smooth-muscle proliferation in patients with pulmonary hypertension. We studied the sites and magnitude of endothelin-1 production in the lungs of patients with various causes of pulmonary hypertension. Methods. We studied the distribution of endothelin1-like immunoreactivity (by immunocytochemical analysis) and endothelin-1 messenger RNA (by in situ hybridization) in lung specimens from 15 control subjects, 11 patients with plexogenic pulmonary arteriopathy (grades 4 through 6), and 17 patients with secondary pulmonary hypertension and pulmonary arteriopathy of grades 1 through 3. Results. In the controls, endothelin-1 -like immunoreactivity was rarely seen in vascular endothelial cells. In the patients with pulmonary hypertension, endothelin-1-like immunoreactivity was abundant, predominantly in endothelial cells of pulmonary arteries with medial thickening and intimal fibrosis. Likewise, endothelin-1 messenger RNA was increased in the patients with pulmonary hypertension and was expressed primarily at sites of endothelin-1 -like immunoreactivity. There was a strong correlation between the intensity of endothelin-1 -like immunoreactivity and pulmonary vascular resistance in the patients with plexogenic pulmonary arteriopathy, but not in those with secondary pulmonary hypertension. Conclusions. Pulmonary hypertension is associated with the increased expression of endothelin-1 in vascular endothelial cells, suggesting that the local production of endothelin-1 may contribute to the vascular abnormalities associated with this disorder.

Original languageEnglish (US)
Pages (from-to)1732-1739
Number of pages8
JournalNew England Journal of Medicine
Volume328
Issue number24
StatePublished - Jun 17 1993

Fingerprint

Endothelin-1
Pulmonary Hypertension
Lung
Endothelial Cells
Pulmonary Artery
Blood Vessels
Tunica Intima
Messenger RNA
Vasoconstrictor Agents
Vascular Resistance
Cell Wall
Muscle Cells
Endothelium
In Situ Hybridization
Smooth Muscle
Fibrosis
Peptides

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Giaid, A., Yanagisawa, M., Langleben, D., Michel, R. P., Levy, R., Shennib, H., ... Stewart, D. J. (1993). Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. New England Journal of Medicine, 328(24), 1732-1739.

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. / Giaid, Adel; Yanagisawa, Masashi; Langleben, David; Michel, René P.; Levy, Robert; Shennib, Hani; Kimura, Sadao; Masaki, Tomoh; Duguid, William P.; Stewart, Duncan J.

In: New England Journal of Medicine, Vol. 328, No. 24, 17.06.1993, p. 1732-1739.

Research output: Contribution to journalArticle

Giaid, A, Yanagisawa, M, Langleben, D, Michel, RP, Levy, R, Shennib, H, Kimura, S, Masaki, T, Duguid, WP & Stewart, DJ 1993, 'Expression of endothelin-1 in the lungs of patients with pulmonary hypertension', New England Journal of Medicine, vol. 328, no. 24, pp. 1732-1739.
Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. New England Journal of Medicine. 1993 Jun 17;328(24):1732-1739.
Giaid, Adel ; Yanagisawa, Masashi ; Langleben, David ; Michel, René P. ; Levy, Robert ; Shennib, Hani ; Kimura, Sadao ; Masaki, Tomoh ; Duguid, William P. ; Stewart, Duncan J. / Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. In: New England Journal of Medicine. 1993 ; Vol. 328, No. 24. pp. 1732-1739.
@article{88bb1a18270b4ea684743b269adeedbf,
title = "Expression of endothelin-1 in the lungs of patients with pulmonary hypertension",
abstract = "Background. Pulmonary hypertension is characterized by an increase in vascular tone or an abnormal proliferation of muscle cells in the walls of small pulmonary arteries. Endothelin-1 is a potent endothelium-derived vasoconstrictor peptide with important mitogenic properties. It has therefore been suggested that endothelin-1 may contribute to increases in pulmonary arterial tone or smooth-muscle proliferation in patients with pulmonary hypertension. We studied the sites and magnitude of endothelin-1 production in the lungs of patients with various causes of pulmonary hypertension. Methods. We studied the distribution of endothelin1-like immunoreactivity (by immunocytochemical analysis) and endothelin-1 messenger RNA (by in situ hybridization) in lung specimens from 15 control subjects, 11 patients with plexogenic pulmonary arteriopathy (grades 4 through 6), and 17 patients with secondary pulmonary hypertension and pulmonary arteriopathy of grades 1 through 3. Results. In the controls, endothelin-1 -like immunoreactivity was rarely seen in vascular endothelial cells. In the patients with pulmonary hypertension, endothelin-1-like immunoreactivity was abundant, predominantly in endothelial cells of pulmonary arteries with medial thickening and intimal fibrosis. Likewise, endothelin-1 messenger RNA was increased in the patients with pulmonary hypertension and was expressed primarily at sites of endothelin-1 -like immunoreactivity. There was a strong correlation between the intensity of endothelin-1 -like immunoreactivity and pulmonary vascular resistance in the patients with plexogenic pulmonary arteriopathy, but not in those with secondary pulmonary hypertension. Conclusions. Pulmonary hypertension is associated with the increased expression of endothelin-1 in vascular endothelial cells, suggesting that the local production of endothelin-1 may contribute to the vascular abnormalities associated with this disorder.",
author = "Adel Giaid and Masashi Yanagisawa and David Langleben and Michel, {Ren{\'e} P.} and Robert Levy and Hani Shennib and Sadao Kimura and Tomoh Masaki and Duguid, {William P.} and Stewart, {Duncan J.}",
year = "1993",
month = "6",
day = "17",
language = "English (US)",
volume = "328",
pages = "1732--1739",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "24",

}

TY - JOUR

T1 - Expression of endothelin-1 in the lungs of patients with pulmonary hypertension

AU - Giaid, Adel

AU - Yanagisawa, Masashi

AU - Langleben, David

AU - Michel, René P.

AU - Levy, Robert

AU - Shennib, Hani

AU - Kimura, Sadao

AU - Masaki, Tomoh

AU - Duguid, William P.

AU - Stewart, Duncan J.

PY - 1993/6/17

Y1 - 1993/6/17

N2 - Background. Pulmonary hypertension is characterized by an increase in vascular tone or an abnormal proliferation of muscle cells in the walls of small pulmonary arteries. Endothelin-1 is a potent endothelium-derived vasoconstrictor peptide with important mitogenic properties. It has therefore been suggested that endothelin-1 may contribute to increases in pulmonary arterial tone or smooth-muscle proliferation in patients with pulmonary hypertension. We studied the sites and magnitude of endothelin-1 production in the lungs of patients with various causes of pulmonary hypertension. Methods. We studied the distribution of endothelin1-like immunoreactivity (by immunocytochemical analysis) and endothelin-1 messenger RNA (by in situ hybridization) in lung specimens from 15 control subjects, 11 patients with plexogenic pulmonary arteriopathy (grades 4 through 6), and 17 patients with secondary pulmonary hypertension and pulmonary arteriopathy of grades 1 through 3. Results. In the controls, endothelin-1 -like immunoreactivity was rarely seen in vascular endothelial cells. In the patients with pulmonary hypertension, endothelin-1-like immunoreactivity was abundant, predominantly in endothelial cells of pulmonary arteries with medial thickening and intimal fibrosis. Likewise, endothelin-1 messenger RNA was increased in the patients with pulmonary hypertension and was expressed primarily at sites of endothelin-1 -like immunoreactivity. There was a strong correlation between the intensity of endothelin-1 -like immunoreactivity and pulmonary vascular resistance in the patients with plexogenic pulmonary arteriopathy, but not in those with secondary pulmonary hypertension. Conclusions. Pulmonary hypertension is associated with the increased expression of endothelin-1 in vascular endothelial cells, suggesting that the local production of endothelin-1 may contribute to the vascular abnormalities associated with this disorder.

AB - Background. Pulmonary hypertension is characterized by an increase in vascular tone or an abnormal proliferation of muscle cells in the walls of small pulmonary arteries. Endothelin-1 is a potent endothelium-derived vasoconstrictor peptide with important mitogenic properties. It has therefore been suggested that endothelin-1 may contribute to increases in pulmonary arterial tone or smooth-muscle proliferation in patients with pulmonary hypertension. We studied the sites and magnitude of endothelin-1 production in the lungs of patients with various causes of pulmonary hypertension. Methods. We studied the distribution of endothelin1-like immunoreactivity (by immunocytochemical analysis) and endothelin-1 messenger RNA (by in situ hybridization) in lung specimens from 15 control subjects, 11 patients with plexogenic pulmonary arteriopathy (grades 4 through 6), and 17 patients with secondary pulmonary hypertension and pulmonary arteriopathy of grades 1 through 3. Results. In the controls, endothelin-1 -like immunoreactivity was rarely seen in vascular endothelial cells. In the patients with pulmonary hypertension, endothelin-1-like immunoreactivity was abundant, predominantly in endothelial cells of pulmonary arteries with medial thickening and intimal fibrosis. Likewise, endothelin-1 messenger RNA was increased in the patients with pulmonary hypertension and was expressed primarily at sites of endothelin-1 -like immunoreactivity. There was a strong correlation between the intensity of endothelin-1 -like immunoreactivity and pulmonary vascular resistance in the patients with plexogenic pulmonary arteriopathy, but not in those with secondary pulmonary hypertension. Conclusions. Pulmonary hypertension is associated with the increased expression of endothelin-1 in vascular endothelial cells, suggesting that the local production of endothelin-1 may contribute to the vascular abnormalities associated with this disorder.

UR - http://www.scopus.com/inward/record.url?scp=0027324745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027324745&partnerID=8YFLogxK

M3 - Article

VL - 328

SP - 1732

EP - 1739

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 24

ER -